Do we really need five TNF antagonists? Or more insight into the use of existing options?

Eric M. Ruderman*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

1 Scopus citations
Original languageEnglish (US)
Article numberkeq016
Pages (from-to)1028-1029
Number of pages2
JournalRheumatology
Volume49
Issue number6
DOIs
StatePublished - Feb 19 2010

Funding

Disclosure statement: E.M.R. has received consulting fees from Abbott Immunology, Amgen/Wyeth and UCB. He has received research funding from Abbott Immunology and Centocor.

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Rheumatology

Cite this